BANGALORE, India, Nov. 25, 2021 /PRNewswire/ -- Orphan Drugs Market Segment by Type - Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardio-vascular, Metabolic Disorders, Endocrinology, Infectious Diseases, Others, Application - Hospital Pharmacies, Retail pharmacies, Others. The report covers global opportunity analysis and industry forecasts from 2021 to 2027. It is published in Valuates Reports in the Pharmaceuticals & Biotech Category.

Valuates Reports

The global Orphan Drugs market size is projected to reach USD 241610 million by 2027, from USD 122720 million in 2020, at a CAGR of 9.7% during 2021-2027.

Major Factors Driving The Growth Of The Orphan Drugs Market are

Government authorities in numerous nations throughout the world are pushing the research and marketing of these treatments, as well as giving orphan drugs market exclusivity. This in turn is expected to drive the orphan drug market.

For a variety of reasons, the orphan medicine market has become increasingly lucrative. Clinical trials for orphan medications are significantly less expensive than for other diseases since trial sizes are naturally smaller than for more common diseases with larger patient populations. Orphan drugs have an advantage in regulatory evaluation because of their small clinical trials and lack of competition.

Additionally, the market is expected to rise significantly due to an increase in the number of medications developed for uncommon blood illnesses and diseases previously thought to be incurable.

Get Your Sample Today:


An orphan drug is a pharmaceutical product used for the diagnosis, prevention, and treatment of various rare disorders or diseases, according to the European Organization for Rare Diseases. These diseases are distinct from other diseases in that they have a very low prevalence rate relative to other diseases, and so are purchased by a very tiny patient population. Government authorities in a number of nations around the world, on the other hand, are pushing the development and commercialization of these drugs. This in turn is expected to drive the growth of the orphan drug market. 

The Orphan Drug Act (ODA) was passed by the US Food and Drug Administration (FDA) in 1983. The purpose was to promote the discovery of novel drugs for rare diseases. The Orphan Drug Act (ODA) permits developers to recoup costs by designating their drugs as orphans. This stimulates research into regions where there may be no therapy possibilities otherwise. If there is no commercially accessible treatment for a condition that affects more than 200,000 people, the ODA also covers medications.

Increasing R&D initiatives to propel worldwide orphan drug market expansion. Increased R&D investments by major companies for orphan drug development of unique product offerings is one of the essential driving factors prevailing in the worldwide market. Since the public's awareness of rare diseases has grown, a number of clinical-stage biopharmaceutical startups and existing market players have developed strong pipeline prospects for orphan medications in various stages of development. This growing interest in rare condition treatments is due to the fact that, in contrast to standard pharmaceutical portfolios, important pharmacological breakthroughs resulting in blockbuster drug development are far more likely in rare disorders.

Browse The Table Of Contents And List Of Figures At


Based on region, North America is expected to be the most lucrative. Throughout the forecast period, The increasing occurrence of uncommon illnesses is driving this region's market growth.

Based on type, the oncology segment is expected to be the most lucrative segment. The dominance is attributable to the existence of multiple oncology treatments in important businesses' product development pipelines, as well as a substantial number of orphan drugs devoted to cancer treatment.

Based on application, The hospital pharmacy segment is expected to be the most lucrative. The fundamental reason for this domination is that a considerable number of medications must be administered intravenously by skilled healthcare workers in hospitals.

Inquire For Customization:

Orphan Drugs Market Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2016-2027. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region. North America, Europe, China and Japan are the major regions studied in the research report.

Orphan Drugs Market By Company

●  Novartis
●  Bristol-Myers Squibb Company
●  Celgene
●  F. Hoffmann-La Roche
●  Pfizer
●  Sanofi
●  Alexion Pharmaceuticals
●  Eli Lilly and Company
●  Novo Nordisk
●  AstraZeneca
●  Eisai
●  Daiichi Sankyo Company
●  Bayer
●  GlaxoSmithKline
●  Merck & Co
●  Johnson & Johnson
●  Biogen
●  Takeda
●  Amgen

Inquire For Chapter Cost:

Buy Now for Single User + Covid-19 Impact :


We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.


-  The global Orphan Diseases market size is projected to reach USD 676.3 million by 2027, from USD 260.3 million in 2020, at a CAGR of 14.1% during 2021-2027.

-  The global Cystic Fibrosis Therapeutics market size is projected to reach USD 12680 million by 2027, from USD 5060.5 million in 2020, at a CAGR of 13.5% during 2021-2027.

-  The global rheumatoid arthritis drugs market was valued at USD 57,929 million in 2019, and is projected to reach USD 62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027.

-  The global Amyotrophic Lateral Sclerosis Treatment market size is projected to reach USD 470.1 million by 2027, from USD 285.9 million in 2020, at a CAGR of 6.9% during 2021-2027.

-  The global oncology drugs market was valued at USD 128,352 million in 2019, and is projected to reach USD 222,380 million by 2027, registering a CAGR of 7.4%.

-  Amyotrophic Lateral Sclerosis Drugs Market Size, Status and Forecast 2021-2027

-  Factor VIII Deficiency Treatment Market Size, Status and Forecast 2021-2027

-  Signifor Drugs Market Research Report 2019-2025

-  IV and Oral Iron Drugs Market Size, Status and Forecast 2021-2027

-  Orphan Lung Diseases Treatment Market Size, Status and Forecast 2021-2027

-  Acromegaly and Gigantism Drugs Sales Market Report 2021

-  Castleman Disease Treatment Market Size, Status and Forecast 2021-2027

Click Here To See Related Reports on Orphan Drugs

About Us:

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.

Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.

Contact Us:

Valuates Reports
For U.S. Toll-Free Call 1-(315)-215-3225
For IST Call +91-8040957137
WhatsApp: +91-9945648335
Twitter -
LinkedIn -

Cision View original content:

SOURCE Valuates Reports

Copyright 2021 PR Newswire